ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
124.850,18
0,38%
S&P 500
6.115,07
1,04%
US Dollar vs BRL
5,7667
-0,03%
Bitcoin
96.597,79
-0,02%
Brent Oil
75,09
0,00%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Hoth Therapeutics Inc (HOTH)

  7. Hoth Therapeutics Inc (HOTH) Notícias

HOTH

Hoth Therapeutics (HOTH)

Hoth Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:HOTH
DataHoraFonteTítuloCódigoCompanhia
10/02/202510:22PR Newswire (US)Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer TherapeuticNASDAQ:HOTHHoth Therapeutics Inc
07/02/202518:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
07/02/202518:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HOTHHoth Therapeutics Inc
24/01/202510:29PR Newswire (US)Hoth Therapeutics Regains Compliance with Nasdaq Listing RequirementsNASDAQ:HOTHHoth Therapeutics Inc
21/01/202510:29PR Newswire (US)Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent ApplicationsNASDAQ:HOTHHoth Therapeutics Inc
17/01/202510:29PR Newswire (US)Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025NASDAQ:HOTHHoth Therapeutics Inc
15/01/202518:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
08/01/202515:27PR Newswire (US)Hoth Therapeutics Responds to Market Rumors and Shareholder InquiriesNASDAQ:HOTHHoth Therapeutics Inc
07/01/202514:35AllPennyStocks.comShares Of This Micro Cap More Than Doubled TodayNASDAQ:HOTHHoth Therapeutics Inc
07/01/202510:29PR Newswire (US)Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin ToxicitiesNASDAQ:HOTHHoth Therapeutics Inc
26/12/202409:58PR Newswire (US)Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity TreatmentNASDAQ:HOTHHoth Therapeutics Inc
20/11/202409:38PR Newswire (US)Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve AssetNASDAQ:HOTHHoth Therapeutics Inc
12/11/202418:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOTHHoth Therapeutics Inc
29/10/202413:43PR Newswire (US)Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment StudyNASDAQ:HOTHHoth Therapeutics Inc
15/10/202407:38PR Newswire (US)Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now UnderwayNASDAQ:HOTHHoth Therapeutics Inc
17/09/202408:57PR Newswire (US)Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZNASDAQ:HOTHHoth Therapeutics Inc
05/09/202411:32PR Newswire (US)Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a TrialNASDAQ:HOTHHoth Therapeutics Inc
05/09/202409:03PR Newswire (US)Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001NASDAQ:HOTHHoth Therapeutics Inc
16/08/202417:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:HOTHHoth Therapeutics Inc
15/08/202409:04PR Newswire (US)Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer TherapeuticNASDAQ:HOTHHoth Therapeutics Inc
24/07/202411:30AllPennyStocks.comMicro Cap Already Off To The Races At The BellNASDAQ:HOTHHoth Therapeutics Inc
24/07/202407:30PR Newswire (US)Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's TreatmentNASDAQ:HOTHHoth Therapeutics Inc
16/07/202409:31PR Newswire (US)Hoth Therapeutics Expands Clinical Trial for Cancer PatientsNASDAQ:HOTHHoth Therapeutics Inc
18/06/202407:15Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:HOTHHoth Therapeutics Inc
18/06/202407:10Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:HOTHHoth Therapeutics Inc
18/06/202407:07Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:HOTHHoth Therapeutics Inc
10/06/202409:11PR Newswire (US)Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug DiscoveryNASDAQ:HOTHHoth Therapeutics Inc
01/05/202409:00PR Newswire (US)Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024NASDAQ:HOTHHoth Therapeutics Inc
27/03/202415:00PR Newswire (US)Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross ProceedsNASDAQ:HOTHHoth Therapeutics Inc
27/03/202409:27PR Newswire (US)Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity TreatmentNASDAQ:HOTHHoth Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:HOTH

Seu Histórico Recente

NASDAQ
FFJZX
Lazard Global Balanced I...
USOTC
TWNE
Towne Bancorp (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios